Previous Close | 2.1400 |
Open | 2.2300 |
Bid | 1.7500 x 2200 |
Ask | 2.0000 x 900 |
Day's Range | 1.9500 - 2.2300 |
52 Week Range | 1.4050 - 29.1600 |
Volume | |
Avg. Volume | 254,001 |
Market Cap | 58.966M |
Beta (5Y Monthly) | 1.65 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.3050 |
Earnings Date | Feb 21, 2022 - Feb 25, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 6.50 |
HAYWARD, Calif., May 19, 2022--Pulse Biosciences, Inc. (Nasdaq: PLSE) (the "Company" or "Pulse Biosciences"), a novel bioelectric medicine company commercializing the CellFX® System Powered by Nano-Pulse Stimulation™ (NPS™) technology, announced today two changes to its current rights offering. First, the Company has extended the expiration date of the rights offering from May 23, 2022 to May 26, 2022, at 5:00 p.m., Eastern Time (the "Expiration Date"). Second, the Company has amended the defini
U.S. biotechs and other health care stocks accounted for about 11% of all losses in U.S. equity values during the five-month period analyzed by The Business Journals.
Pulse Biosciences, Inc (PLSE) delivered earnings and revenue surprises of 5.88% and 36.57%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?